Skip to content

Biomarkers of Acute Kidney Injury Following Cardiac Surgery

Biomarkers of Acute Kidney Injury Following Cardiopulmonary Bypass Surgery-supported Cardiac Surgery

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04387149
Enrollment
400
Registered
2020-05-13
Start date
2020-01-06
Completion date
2022-02-28
Last updated
2020-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Biomarkers of Acute Kidney Injury Following Cardiac Surgery

Brief summary

Acute kidney injury occurs in up to 30% of patients undergoing cardiac surgery. Cardiac surgery associated-acute kidney injury (CSA-AKI) is characterized by a sudden and sustained decrease in renal function with insufficient elimination waste products. The problem is that postoperative diagnosis of CSA-AKI is delayed because it relies solely upon the slow and unreliable rise in serum creatinine (SCr) levels that may lead to delayed start in treatment and increased risk of adverse outcomes. We hypothesize that Matrix Metalloproteins (MMPs) -2, -9 and Neutrophil gelatinase-associated lipocalin (NGAL) are associated with and earlier detectors of CSA-AKI compared to levels of SCr.

Detailed description

Cardiopulmonary bypass (CPB), although essential to the performance of most cardiac operations, has been shown to cause injury to other organs, particularly to the kidneys and brain. Matrix Metalloproteins (MMPs) are ubiquitous proteolytic enzymes that degrade extracellular matrix and have been shown to be involved in injury to transplant kidneys. To date, no interventions are available to decrease the risk of cardiac surgery associated-acute kidney injury (CSA-AKI). NGAL is a known indicator of injury to kidney, thus making it a promising biomarker for CSA-AKI. It may be that a single biomarker will not be sensitive and specific across the spectrum of CSA-AKI. This research investigates MMP-2, -9 and Neutrophil gelatinase-associated lipocalin (NGAL) and their association with and earlier detection of CSA-AKI compared to levels of SCr. We hypothesize that increased activity of MMPs are associated with CSA-AKI. Furthermore, MMP-2 and/ or -9 may be predictors and/ or biomarkers for the early detection of CSA-AKI compared to serum levels of creatinine.

Interventions

None listed

Sponsors

University of Saskatchewan
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years

Inclusion criteria

* The inclusion criteria consisted of both sexes, 18-85 years of age, undergoing elective or urgent cardiac surgery with a hemoglobin (Hgb) \>100 g/L.

Exclusion criteria

* The

Design outcomes

Primary

MeasureTime frameDescription
Increased MMP-2 and -9 in patients that develop CSA-AKIPre-CPB, 10 min post-CPB time point, 4 hours post-CPDIncreased MMP-2 and -9 activity in serum and or urine in patients that develop CSA-AKI

Secondary

MeasureTime frameDescription
Increased NGAL levels in patients that develop CSA-AKIPre-CPB, 10 min post-CPB time point, 4 hours post-CPDIncreased NGAL levels in serum and or urine in patients that develop CSA-AKI

Countries

Canada

Contacts

Primary ContactErick D McNair, PhD
erick.mcnair@usask.ca306 966-7637
Backup ContactMike Moser, MD
mike.moser@usask.ca306 655-5320

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026